Compare AU

Compare VNGS vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

Vaughan Nelson Global Smid Fund (Managed Fund)

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vaughan Nelson Global Smid Fund (Managed Fund) (VNGS) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

VNGS

CURE

Popularity

N/A

Low

Pearlers invested

0

83

Median incremental investment

$0

$619.50

Median investment frequency

N/A

Monthly

Median total investment

$0

$1,437.24

Average age group

N/A

> 35


Key Summary

VNGS

CURE

Strategy

VNGS.AX was created on 2022-06-01 by Vaughan. The fund's investment portfolio concentrates primarily on extended market equity. The Fund aims to outperform the MSCI ACWI SMID Cap Index (after fees and expenses and before taxes) on a rolling five-year basis.

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

Monolithic Power Systems Inc (3.37 %)

Element Solutions Inc (3.09 %)

Cushman & Wakefield PLC (2.66 %)

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

Top 3 industries

Other (21.22 %)

Information Technology (19.22 %)

Financials (15.49 %)

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (58.61 %)

United Kingdom of Great Britain and Northern Ireland (11.67 %)

Japan (4.24 %)

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

1.12 %

0.45 %


Key Summary

VNGS

CURE

Issuer

Vaughan

Global X

Tracking index

MSCI ACWI SMID Cap Index

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

1.12 %

0.45 %

Price

$3.29

$51.33

Size

$27.627 million

$36.301 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

- %

4.24 %

Market

ASX

ASX

First listed date

31/05/2022

12/11/2018

Purchase fee

$6.50

$6.50


Community Stats

VNGS

CURE

Popularity

N/A

Low

Pearlers invested

0

83

Median incremental investment

$0

$619.50

Median investment frequency

N/A

Monthly

Median total investment

$0

$1,437.24

Average age group

N/A

> 35


Pros and Cons

VNGS

CURE

Pros

  • Higher exposure to AU market

  • Higher price growth

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

  • Lower exposure to AU market

  • Lower price growth

VNGS

CURE

Higher exposure to AU market

Lower exposure to AU market

Lower exposure to US market

Higher exposure to US market

Higher management fee

Lower management fee

Higher price growth

Lower price growth

Lower distribution yield

Higher distribution yield

Home